The latest from small and Emerging Pharma companies featuring Jeito Capital, Collegium Pharmaceutical, Corium Therapeutics, Sidewinder Therapeutics and Stipple Bio. 

For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs. 

* Jeito Capital Closes $1.2-Bn EU Biopharma Investment Fund 
* Collegium To Acquire ADHD Drug From Corium Therapeutics in $785-M Deal 
* Sidewinder Therapeutics Raises $137 M To Advance Bispecific ADC 
* Stipple Bio Raises $100 M for Precision Oncology Drug Pipeline 

---

Jeito Capital Closes $1.2-Bn EU Biopharma Investment Fund 
Jeito Capital, a private equity fund dedicated to European bio/pharma, has announced the final closing of its second fund Jeito II, which raised $1.2 billion. Jeito II will selectively identify and back 15 to 20 clinical-stage bio/pharma companies, primarily in Europe focused on developing therapies for severe diseases. 

Source: Jeito Captial 

---

Collegium To Acquire ADHD Drug From Corium Therapeutics in $785-M Deal 
Collegium Pharmaceutical, a Stoughton, Massachusetts-based bio/pharmaceutical company, has agreed to acquire Azstarys (serdexmethylphenidate/dexmethylphenidate), a drug for treating attention-deficit/hyperactivity disorder from Corium Therapeutics, a Cambridge, Massachusetts-based bio/pharmaceutical company, in a deal worth up to $785 million ($650 million upfront and $135 million in milestone payments). 

Source: Collegium Pharmaceutical 

---

Sidewinder Therapeutics Raises $137 M To Advance Bispecific ADC  
Sidewinder Therapeutics, a San Diego, California-based bio/pharmaceutical company focused on bispecific antibody-drug conjugates (ADCs) for the treatment of cancer, has announced the closing of an oversubscribed $137 million Series B financing. The round was co-led by Frazier Life Sciences and the Novartis Venture Fund, with participation from the sole Series A investor, OrbiMed, as well as new investors, including Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and Alexandria Venture Investments.  

Source: Sidewinder Therapeutics 

---

Stipple Bio Raises $100 M for Precision Oncology Drug Pipeline 
Stipple Bio, a private bio/pharmaceutical company applying epitope-level capabilities for developing targeted cancer therapies, has closed a $100-million Series A financing. The financing was co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors, Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners, and GordonMD Global Investments, among others.  

The proceeds from the financing, which should fund the company into 2029, will be used to advance its lead candidate, STP-100, an oncology antibody drug conjugate. 

Source: Stipple Bio